Alpha-1-Proteinase Inhibitor (Human)(Takeda)

Massachusetts-based genetic therapy biotech Airna has dosed the first patient in the RepAIR1 Phase I trial of AIR-001, a GalNAc-conjugated oligonucleotide designed to correct the PiZ mutation in SERPINA1 mRNA by recruiting endogenous ADAR enzymes. The firm simultaneously announced that the FDA has granted Orphan Drug Designation to AIR-001 for alpha-1 antitrypsin deficiency (AATD). The open-label study, registered as NCT07431112, is enrolling adults with the PiZZ genotype across sites in Australia and the United Kingdom, with planned expansion to approximately 20 sites in 11 countries and a target enrolment of 54 patients. Primary endpoints cover safety, pharmacokinetics, and pharmacodynamic changes across total alpha-1 antitrypsin (AAT), functional AAT, Z-AAT, and M-AAT. AATD is caused by mutations in SERPINA1, with the PiZ variant driving the most common and severe form of the disease. The resulting Z-AAT protein misfolds and accumulates in hepatocytes, causing progressive liver injury, while reduced circulating functional AAT leaves lung tissue vulnerable to protease-mediated destruction. The dual organ involvement is a defining feature of AATD biology and a persistent challenge for therapeutic development. Research context The mechanistic logic behind AIR-001 maps directly onto the molecular basis of PiZZ (homozygous PiZ mutation) disease. The PiZ mutation is a single nucleotide substitution — a G-to-A change at the DNA level that produces a glutamate-to-lysine substitution in the AAT protein, driving its misfolding and polymerisation. ADAR enzymes catalyse adenosine-to-inosine editing of RNA, which ribosomes read as guanosine, making the PiZ site a tractable target for A-to-I correction without altering genomic sequence. AIR-001 exploits this by deploying a GalNAc-conjugated guide oligonucleotide to recruit endogenous ADAR to the relevant position on SERPINA1 mRNA. GalNAc conjugation provides hepatocyte-selective uptake via the asialoglycoprotein receptor, concentrating the drug in the liver where AAT is produced. If editing is efficient enough to restore meaningful M-AAT output, the approach could simultaneously reduce pathological Z-AAT accumulation and raise circulating functional AAT — addressing both disease compartments with a single subcutaneous agent. AIRNA’s platform was founded on research by Thorsten Stafforst at the University of Tübingen and Jin Billy Li at Stanford, whose work established the feasibility of recruiting native ADAR for therapeutic RNA correction. The reversibility of RNA editing is a design feature with practical implications. Because SERPINA1 mRNA is continuously transcribed, editing must be maintained through repeat dosing — but this also means the intervention can be stopped, a consideration relevant to safety monitoring in early-phase trials and to future combination strategies. Standard of care and where current therapies fall short The only approved disease-specific therapy for AATD remains intravenous plasma-derived AAT augmentation, first approved in 1987 and available in the US through products including Prolastin-C (Grifols), Aralast NP and Glassia (Takeda), and Zemaira (CSL Behring). Weekly IV infusions partially compensate for low circulating AAT in the lung but do not address the toxic gain-of-function from Z-AAT accumulation in the liver. No pharmacological therapy for AATD-associated liver disease has been approved. For patients with end-stage organ involvement, transplantation remains the only definitive option. The dependence on human plasma supply, the burden of weekly infusions, and the absence of any liver-directed therapy define the gaps that newer modalities are attempting to fill. AIR-001’s subcutaneous route and its theoretical capacity to act on both lung and liver disease position it differently from augmentation therapy, though whether preclinical signals translate to meaningful clinical benefit in both compartments remains to be established in RepAIR1 and subsequent trials. Competitive landscape The most clinically advanced novel agent in AATD is fazirsiran (ARO-AAT), an RNAi therapeutic developed by Arrowhead Pharmaceuticals in partnership with Takeda. Fazirsiran uses siRNA to suppress SERPINA1 expression in hepatocytes, reducing Z-AAT production and liver accumulation. It completed Phase II evaluation in the SEQUOIA trial, where it demonstrated reductions in hepatic Z-AAT and improvements in liver enzyme levels, and holds FDA Breakthrough Therapy Designation for AATD-associated liver disease. An NDA submission is anticipated, which would make fazirsiran the first approved pharmacological treatment for AATD liver disease. The mechanistic distinction between fazirsiran and AIR-001 is significant: fazirsiran suppresses all SERPINA1 expression indiscriminately, reducing Z-AAT but not restoring M-AAT, whereas AIR-001 aims to convert Z-AAT mRNA into M-AAT mRNA, theoretically producing functional protein rather than simply reducing a toxic one. Whether that distinction produces a clinically meaningful difference in lung outcomes — where circulating AAT levels matter — is one of the central questions AIR-001’s development will need to answer. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website